Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
116M
-
Shares change
-
+2.09M
-
Total reported value, excl. options
-
$126M
-
Value change
-
+$2.11M
-
Put/Call ratio
-
0.25
-
Number of buys
-
22
-
Number of sells
-
-24
-
Price
-
$1.09
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q1 2023
71 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q1 2023.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 116M shares
of 1.57B outstanding shares and own 7.38% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (39M shares), BAILLIE GIFFORD & CO (17.1M shares), NEA Management Company, LLC (17.1M shares), BAKER BROS. ADVISORS LP (9.83M shares), PFM Health Sciences, LP (5.99M shares), Long Focus Capital Management, LLC (5.44M shares), BANK OF AMERICA CORP /DE/ (5.4M shares), Rock Springs Capital Management LP (2.79M shares), MORGAN STANLEY (2.25M shares), and Endurant Capital Management LP (1.66M shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.